Congress gives drug makers a tax break—with vague affordability rules
S. 3325 — Expanding Access to Affordable Drugs and Medical Devices Act · Filed by Jacky Rosen (D-NV) · 1 cosponsor · Introduced Dec 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a new tax-exempt status for organizations that manufacture or distribute drugs and medical devices primarily to make them affordable. These 'public interest' organizations would be exempt from normal tax rules if they meet affordability and governance standards, and they must agree to give the government priority access to purchase designated drugs at cost-plus pricing during national emergencies or shortages.
Why we flagged it
The bill's core mechanism is a new tax-exempt classification for drug and device makers, framed as a public-interest measure but functionally a tax carve-out for a specific industry sector with vague affordability guardrails.
What the text implies
- The 'affordability' standard is defined by Treasury/HHS guidance issued after enactment, not in statute—allowing regulatory discretion to expand or contract eligibility without congressional action.
- Organizations can receive up to 1% of gross receipts from non-permissible sources without losing tax-exempt status, creating a loophole for profit-taking disguised as public interest.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical manufacturers; medical device makers; contract manufacturers in healthcare